Starting Pradaxa - Initiation and dosing in DVT/PE

An image denoting the 'starting Pradaxa (Dabigatran)' section on the site

What is the dosing of Pradaxa in DVT/PE?

Similar to the dosing in atrial fibrillation, both 150 mg BID and 110 mg BID are indicated.1

2 indicated doses

An image showing the indicated doses for Pradaxa (Dabigatran): 150mg BID and 110 mg BID

 

  • Patients aged ≥80 years
  • Patients who receive verapamil concomitantly
  • Lower dose can be considered in other patients at increased risk of bleeding (see Pradaxa SPC)

How easy is it to initiate Pradaxa in my DVT/PE patients?

Pradaxa can be easily started following at least 5 days of heparin (LMWH).1 Give Pradaxa 0–2 hours prior to the time at which the dose of LMWH would have been due.1

 

An image showing progression from treatment with LMWH to starting Pradaxa (Dabigatran)

 

How do my patients take Pradaxa?

Pradaxa can be taken with or without food. Pradaxa should be swallowed as a whole with water, to facilitate delivery to the stomach.1

Patients should be instructed not to open the capsule as this may increase the risk of bleeding.1

What happens if my patient misses a dose?

A forgotten dose may still be taken up to 6 hours prior to the next scheduled dose. From 6 hours prior to the next scheduled dose on, the missed dose should be omitted.1 No double dose should be taken to make up for missed individual doses.1

 

 

Can I prescribe Pradaxa in my patients with renal impairment?

Patients with mild to moderate renal impairment can be treated with Pradaxa however, it is contraindicated in those with severe renal impairment (CrCL <30mL/min). Renal function should therefore be assessed by calculating the CrCL prior to initiation of treatment with Pradaxa to exclude patients with severe renal impairment.1

While on treatment the patient’s renal function should also be assessed in certain clinical situations when you suspect that their renal function could decline or deteriorate.1

References: 
  1. Pradaxa Summary of Product Characteristics 2016. Boehringer Ingelheim.